Tonix Pharmaceuticals Holding Corp. (TNXP) Form 8-K — Oct 15, 2026

$TNXPForm 8-KItems 2.02, 8.01Filed Oct 15, 2026, 7:00 AM ET0001493152-26-047139Original filing

Tonix Pharmaceuticals disclosed preliminary Q3 2026 results in an 8-K filed October 15, 2026, estimating TONMYA net revenue of $14.0 million to $15.0 million for the quarter ended September 30, 2026. The company also estimated cash and cash equivalents of approximately $162.8 million as of quarter end, providing an early read on its liquidity during the TONMYA commercial launch.

Key figures

Revenue: $14.0-15.0 million (TONMYA net revenue, preliminary, quarter ended September 30, 2026)
Cash Position: 162800000

AI analysis

Red flags1 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.